| |
|
|
|
Catabasis Pharma  
|
|
1.59 0.09 (0.06%) |
11-27 13:00 |
|
Open: |
1.51 |
Pre close: |
1.5 |
Target:
|
4.90
|
|
High: |
1.63 |
Low: |
1.51 |
Resistance:
|
4.19
6.01
|
|
Volume: |
1,443,953 |
Market Cap: |
32M |
Support:
|
1.25
1.04
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.47
 |
MACD |
MACD(12,26):
|
-0.69 |
|
MA(20): |
1.40 |
Signal(12,26,9): |
-0.88 |
|
MA(100): |
5.32  |
Stochastic Oscillator |
%K(14,3):
|
80.97 |
|
MA(250): |
5.50 |
%D(3): |
76.67 |
|
Average Volume(K) |
3-Month: |
127650
|
52-Week |
High:
|
8.59 |
|
10-Days: |
140926 |
Low: |
1.25 |
|
RSI |
RSI(14):
|
28.86 |
Change(%): |
-73.9 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.141 |
Return on Equity (ttm) |
-79.8 |
Shares Out. (M) |
19.08 |
|
EPS Est. Current Year |
-1.390 |
Return on Assets (ttm) |
-43.7 |
Shares Float (M) |
20.06 |
|
EPS Est. Next Year |
-1.100 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.14 |
|
EPS Est. Next Quarter |
-0.330 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
45.65 |
|
Forward EPS |
-2.350 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
644 |
|
Book Value (p.s.) |
2.460 |
EBITDA (p.s.) |
-1.844 |
P/E |
-0.74 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.65 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-32.19 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-19.34 |
P/CF |
-0.94 |
|
|
|
|
|
|
